Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy

Trial Profile

Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Trilaciclib (Primary) ; Carboplatin; Gemcitabine
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors G1 Therapeutics
  • Most Recent Events

    • 10 Jan 2017 According to a G1 Therapeutics media release, status changed from not yet recruiting to recruiting.
    • 06 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top